We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Lateral Flow Test Could Diagnose Alzheimer’s 10-20 Years before Symptoms Emerge

By LabMedica International staff writers
Posted on 15 Jun 2023

The ability to detect Alzheimer’s disease early is vital for enabling interventions that could prevent the debilitating memory loss and disorientation associated with the condition. More...

Now, a new lateral flow test being developed for Alzheimer’s could potentially diagnose the disease 10-20 years before symptoms emerge.

Aptamer Group (York, UK) in collaboration with Neuro-Bio (Oxford, UK) has successfully engineered Optimer binders that could pave the way for a lateral flow test for early diagnosis of Alzheimer’s disease. Optimer binders are next-generation aptamers characterized by their high affinity, specificity, stability, and cost-effective production. They enable researchers to meet the demand for highly sensitive reagents in point-of-care diagnostics that can target novel molecules, including small ones, thereby facilitating the development of innovative lateral flow device (LFD) tests for various diseases and functions.

Aptamer has developed a panel of Optimer binders for a peptide known as 'T14' which is a novel biomarker for Alzheimer’s disease. The peptide was discovered and is being further validated by Neuro-Bio. The functionality and specific binding capabilities of these Optimer binders to the target biomarker have been demonstrated and patented by partners at Neuro-Bio. The binders' subsequent integration into a standard lateral flow test will boost the clinical and commercial development of rapid diagnostic tests for Alzheimer's disease. These tests would involve simple nasal sampling and could diagnose the disease as early as 10-20 years before any symptoms appear.

“We are pleased to be able to support the team at Neuro-Bio with the development of Optimer binders to enable their revolutionary diagnostic for Alzheimer’s disease,” said Dr. Rob Quinn, Interim Chief Executive Officer of Aptamer Group. “Optimer binders have proven performance in lateral flow test formats and our success in delivering functional Optimer binders to Neuro-Bio’s biomarker facilitates further diagnostic development. With an increasingly aging population and no current tests available for early-stage diagnosis, the advancement of new biomarkers and diagnostics in this field offers hope to the millions of patients and their loved ones worldwide.”

“We’re delighted to be working with Aptamer Group on this potentially game-changing technology to combat one of the biggest unmet medical needs of our time. It’s a further example of UK ingenuity and teamwork for highly innovative and disruptive science,” said Baroness Susan Greenfield, CEO of Neuro-Bio.

Related Links:
Aptamer Group
Neuro-Bio


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Hepatitis A Rapid Test
Anti-HAV IgM Rapid Test Kit
New
Enterovirus Test
Quanty Enterovirus System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: An algorithm within the Check4 platform interprets data from the cartridge and sends test results to users by text or email (Photo courtesy of IdentifySensors)

Digital Diagnostic Platform Uses Electronic Technology for Rapid Disease Detection

Traditional diagnostic methods often fall short in providing rapid, accurate detection of infectious diseases, leading to delays in treatment and increased transmission. Now, a groundbreaking digital diagnostics... Read more

Technology

view channel
Image: The second-generation sampler currently under development (Photo courtesy of Breathe BioMedical)

Breath Test to Enable Early Detection of Breast Cancer

Mammograms often fail to detect breast cancer in women with dense breast tissue, missing up to 60% of cases due to reduced image clarity. Breath analytics has the potential to allow for timely detection... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.